MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3109/09273948.2010.483314

Медицинская библиотека · Ocular immunology and inflammation · 2010

Clinical experience with adalimumab in the treatment of ocular Behçet disease.

Bawazeer Ahmed, Raffa Lina H, Nizamuddin S H M

Сравнительное исследованиеСтатьяПеревод в очереди

Аннотация

PURPOSE: To describe the clinical outcome of refractory ocular Behçet disease with adalimumab therapy.

METHOD: Retrospective review of records.

RESULTS

Twenty-one eyes of 11 male patients with ocular Behçet disease received adalimumab therapy. Of the 21 eyes, 17 had improvement of visual acuity by more than 3 lines after the average follow-up of 10.8 months. Ten out of 11 patients showed complete resolution of inflammation by 4 weeks. The dosages of corticosteroids and immunosuppressive drugs were reduced in most of the patients and stopped altogether in 3 and 6 patients, respectively. One patient on infliximab showed improvement of inflammation after switching over to adalimumab. No serious side effects were observed in any of the patients.

CONCLUSION

Adalimumab appears to be effective in Behçet disease. It has been shown to improve visual acuity and also to have a corticosteroid and immunosuppressive sparing effect. It can induce and maintain sustained remission of the disease.

Для цитирования: Bawazeer Ahmed, Raffa Lina H, Nizamuddin S H M. Clinical experience with adalimumab in the treatment of ocular Behçet disease.. Ocular immunology and inflammation. 2010. DOI: 10.3109/09273948.2010.483314.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.